1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Encouraging Survival Data For Lynparza in Metastatic Breast Cancer

 
• By John Davis

OlympiAD data update backs AZ/Merck & Co.'s PARP inhibitor in metastatic breast cancer, but study not powered to give definitive answer about its effects on overall survival.  

Breast carcinoma
Inflammatory breast carcinoma tissue • Source: Shutterstock

Although the Phase III OlympiAD study wasn't powered to show a statistically significant effect on survival, updated overall survival (OS) data from the trial are "another encouraging marker" for the use of AstraZeneca PLC/Merck & Co. Inc.'s PARP inhibitor, Lynparza (olaparib) in BRCA-mutated, HER2-negative metastatic breast cancer, the companies say.

The final OS results from the OlympiAD study found that Lynparza therapy was associated with a median OS of 19.3 months, compared with 17.1 months in patients treated with chemotherapy (HR 0.90; 95% CI 0.66-1.23; p = 0.513), the companies report. The analysis, presented at the American Association for Cancer Research (AACR) meeting in Chicago on Apr

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

More from R&D